JP2020523303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523303A5 JP2020523303A5 JP2019566745A JP2019566745A JP2020523303A5 JP 2020523303 A5 JP2020523303 A5 JP 2020523303A5 JP 2019566745 A JP2019566745 A JP 2019566745A JP 2019566745 A JP2019566745 A JP 2019566745A JP 2020523303 A5 JP2020523303 A5 JP 2020523303A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- molecular weight
- glycol
- low molecular
- insoluble polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 12
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- -1 voltezomib Chemical compound 0.000 claims 6
- 229920003176 water-insoluble polymer Polymers 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 229920000359 diblock copolymer Polymers 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 229960004528 vincristine Drugs 0.000 claims 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 229940035674 anesthetics Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 2
- 229960003150 bupivacaine Drugs 0.000 claims 2
- 229960001747 cinchocaine Drugs 0.000 claims 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 claims 2
- 229950010160 dimethocaine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 229960004194 lidocaine Drugs 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 229960004919 procaine Drugs 0.000 claims 2
- 229960002372 tetracaine Drugs 0.000 claims 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 1
- ZWAOHEXOSAUJHY-UHFFFAOYSA-N 1-(3,4-dihydroxy-5-methyl-2-oxolanyl)-5-fluoropyrimidine-2,4-dione Chemical compound OC1C(O)C(C)OC1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-UHFFFAOYSA-N 0.000 claims 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229960003831 articaine Drugs 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002023 chloroprocaine Drugs 0.000 claims 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960002409 mepivacaine Drugs 0.000 claims 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 229940053973 novocaine Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960003981 proparacaine Drugs 0.000 claims 1
- 229950003255 propoxycaine Drugs 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 229960001549 ropivacaine Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 229940072358 xylocaine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518800P | 2017-06-13 | 2017-06-13 | |
| US62/518,800 | 2017-06-13 | ||
| PCT/CA2018/050714 WO2018227293A1 (en) | 2017-06-13 | 2018-06-13 | Polymeric paste compositions for drug delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523303A JP2020523303A (ja) | 2020-08-06 |
| JP2020523303A5 true JP2020523303A5 (cg-RX-API-DMAC7.html) | 2021-07-26 |
| JP7254719B2 JP7254719B2 (ja) | 2023-04-10 |
Family
ID=64658910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566745A Active JP7254719B2 (ja) | 2017-06-13 | 2018-06-13 | 薬物送達用のポリマーペースト組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11167034B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3638311A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7254719B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110740752B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018285975B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019026225A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3067269C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018227293A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201505527D0 (en) | 2015-03-31 | 2015-05-13 | Jmedtech Pte Ltd | Composition |
| US20200155449A1 (en) | 2015-11-16 | 2020-05-21 | Medincell | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| AU2018285975B2 (en) * | 2017-06-13 | 2023-11-16 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
| WO2019071245A1 (en) | 2017-10-06 | 2019-04-11 | Foundry Therapeutics, Inc. | IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS |
| CN116650732A (zh) | 2018-01-08 | 2023-08-29 | 铸造疗法股份有限公司 | 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法 |
| US12458589B2 (en) | 2018-05-12 | 2025-11-04 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled release of therapeutic agents |
| WO2020047013A1 (en) | 2018-08-28 | 2020-03-05 | Foundry Therapeutics, Inc. | Polymer implants |
| CN119950395A (zh) * | 2019-04-11 | 2025-05-09 | 铸造疗法股份有限公司 | 用于治疗癌症和相关症状和病症的治疗剂的局部、持续、受控释放的可植入贮存库 |
| CA3167259A1 (en) * | 2020-02-07 | 2021-08-12 | Veronika SCHMITT | Mucoadhesive polymeric drug delivery compositions and methods |
| WO2024168423A1 (en) * | 2023-02-14 | 2024-08-22 | 1376683 B.C. Ltd | Topical copolymer formulations for hydrophobic drug delivery |
| WO2025058571A1 (en) * | 2023-09-15 | 2025-03-20 | Agency For Science, Technology And Research | Polymer composition comprising a thermogelling polymer and a tyrosine kinase inhibitor, and related methods thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6217911B1 (en) | 1995-05-22 | 2001-04-17 | The United States Of America As Represented By The Secretary Of The Army | sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| US6187640B1 (en) | 1998-11-17 | 2001-02-13 | Fujitsu Limited | Semiconductor device manufacturing method including various oxidation steps with different concentration of chlorine to form a field oxide |
| DE19701912C1 (de) | 1997-01-10 | 1998-05-14 | Jenapharm Gmbh | Injizierbares Implantat |
| US6193991B1 (en) | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
| US6451335B1 (en) | 1998-07-02 | 2002-09-17 | Euro-Celtique S.A. | Formulations and methods for providing prolonged local anesthesia |
| US6349306B1 (en) | 1998-10-30 | 2002-02-19 | Aprisma Management Technologies, Inc. | Method and apparatus for configuration management in communications networks |
| KR100360827B1 (ko) | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
| KR100416242B1 (ko) * | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
| DE60220519T2 (de) | 2001-04-20 | 2007-09-27 | The University Of British Columbia, Vancouver | Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe |
| US6623729B2 (en) | 2001-07-09 | 2003-09-23 | Korea Advanced Institute Of Science And Technology | Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer |
| US6913760B2 (en) | 2001-08-06 | 2005-07-05 | New England Medical Hospitals, Inc. | Drug delivery composition |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| RU2355385C2 (ru) | 2002-11-06 | 2009-05-20 | Алза Корпорейшн | Композиции пролонгированного действия с контролируемым высвобождением |
| DK1635875T3 (da) * | 2003-06-26 | 2009-01-12 | Psivida Inc | In-situ-geldannende lægemiddeladministrationssystem |
| AU2003272127A1 (en) * | 2003-10-24 | 2005-05-11 | Samyang Corporation | Polymeric composition for drug delivery |
| AU2004313245B2 (en) | 2003-12-30 | 2011-04-14 | Durect Corporation | Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH |
| EP1604693A1 (en) * | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
| US20090285873A1 (en) * | 2008-04-18 | 2009-11-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide) |
| US8846068B2 (en) | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| RU2504360C2 (ru) * | 2008-08-12 | 2014-01-20 | Новартис Аг | Фармацевтические композиции |
| US9161903B2 (en) | 2008-10-31 | 2015-10-20 | Warsaw Orthopedic, Inc. | Flowable composition that hardens on delivery to a target tissue site beneath the skin |
| US8980317B2 (en) | 2008-12-23 | 2015-03-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating infections comprising a local anesthetic |
| US8623396B2 (en) | 2010-12-03 | 2014-01-07 | Warsaw Orthopedic, Inc. | Compositions and methods for delivering clonidine and bupivacaine to a target tissue site |
| US10449152B2 (en) | 2014-09-26 | 2019-10-22 | Covidien Lp | Drug loaded microspheres for post-operative chronic pain |
| CN106511261A (zh) * | 2016-12-06 | 2017-03-22 | 贵阳中医学院 | 一种替代针灸埋植用羊肠线的可注射原位凝胶 |
| AU2018285975B2 (en) * | 2017-06-13 | 2023-11-16 | The University Of British Columbia | Polymeric paste compositions for drug delivery |
-
2018
- 2018-06-13 AU AU2018285975A patent/AU2018285975B2/en active Active
- 2018-06-13 BR BR112019026225-3A patent/BR112019026225A2/pt not_active Application Discontinuation
- 2018-06-13 EP EP18817738.0A patent/EP3638311A4/en active Pending
- 2018-06-13 CN CN201880039808.7A patent/CN110740752B/zh active Active
- 2018-06-13 CA CA3067269A patent/CA3067269C/en active Active
- 2018-06-13 WO PCT/CA2018/050714 patent/WO2018227293A1/en not_active Ceased
- 2018-06-13 US US16/619,427 patent/US11167034B2/en active Active
- 2018-06-13 JP JP2019566745A patent/JP7254719B2/ja active Active
-
2021
- 2021-10-08 US US17/497,766 patent/US20220152207A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523303A5 (cg-RX-API-DMAC7.html) | ||
| US8574550B2 (en) | Biocompatible polymeric contrast agents and radiopaque materials for medical services | |
| US8674032B2 (en) | Biodegradable multi-block co-polymers | |
| Ying et al. | Scaffolds from electrospun polyhydroxyalkanoate copolymers: fabrication, characterization, bioabsorption and tissue response | |
| Shasteen et al. | Controlling degradation rate of poly (lactic acid) for its biomedical applications | |
| RU2435797C2 (ru) | Резорбируемые блоксополимеры простых и сложных полиэфиров и их применение для изготовления медицинских имплантатов | |
| US9491966B2 (en) | Dihydroxybenzoate polymers and uses thereof | |
| ES2771477T3 (es) | Composiciones de polímeros antimicrobianos y su uso | |
| CN111432807A (zh) | 用于控制释放治疗剂的可植入贮库 | |
| JP2007182442A5 (cg-RX-API-DMAC7.html) | ||
| JP2009522071A (ja) | 生体吸収性の薬物運搬デバイス | |
| BR112012010268B1 (pt) | Dispositivos médicos implantáveis compreendendo copolímeros de polietileno diglicolato absorvíveis e barreira de adesão antimicrobiana | |
| EP2609162A2 (en) | Novel medical device coatings | |
| Nagahama et al. | Impacts of stereoregularity and stereocomplex formation on physicochemical, protein adsorption and cell adhesion behaviors of star-shaped 8-arms poly (ethylene glycol)–poly (lactide) block copolymer films | |
| JP2009522070A (ja) | 溶媒キャストチューブを有する生体吸収性の薬物運搬デバイスの製法 | |
| JP5217149B2 (ja) | 生分解性球状粒子 | |
| US20180028720A1 (en) | Anhydrous biocompatible composite materials | |
| KR102248030B1 (ko) | 표면 개질된 무기 나노입자 및 생분해성 고분자를 포함하는 생체이식물, 및 이의 제조방법 | |
| JP2009522069A (ja) | 溶媒キャストフィルムを有する生体吸収性の薬物運搬デバイスの製法 | |
| WO2010014703A2 (en) | Medical articles comprising biodegradable block copolymers | |
| JP2023513175A5 (cg-RX-API-DMAC7.html) | ||
| Intaravichien et al. | Preparation and Characterization of Stereocomplex Polylactide-b-Poly (ethylene glycol)-b-Polylactide Triblock Copolymer Films for Potential Used as Drug Delivery Systems | |
| Kasperczyk | Novel Poly (L-lactide-co-ε-caprolactone) Matrices Obtained with the Use of Zr [Acac] 4as Nontoxic Initiator for Long-Term Release of Immunosuppressive Drugs |